Inozyme Pharma, Inc.

Inozyme Pharma engages in the research and development of novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Its lead product candidate is INZ-701, which is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. It engages in the business of developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company was founded by Axel Bolte, Joseph P. Schlessinger, and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Inozyme Pharma (INZY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the following investor conferences:

Inozyme Pharma to Present at Upcoming Investor Conferences

- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 –

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis; low PPi levels are associated with calciphylaxis, a rare, life-threatening complication of ESKD -

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that interim data from the Company's ongoing Phase 1 SEAPORT 1 of INZ-701 in patients with end-stage kidney disease (ESKD) receiving hemodialysis will be presented during a poster session at the American Society of Nephrology (ASN) Kidney Week 2024, which is being held October 24-27, 2024, in San Diego.

Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024

BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings to Inozyme over 20 years of commercial expertise within the biopharma industry.

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors

Stifel initiated coverage on Inozyme Pharma Inc. INZY, saying, “This under-the-radar stock could be worth a look ahead of it.”

Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 from 3:45-4:20 pm ET.

Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference

Inozyme Pharma, Inc. interim data from the phase 1 SEAPORT-1 study, using INZ-701 for the treatment of patients with end-stage kidney disease with hemodialysis with calciphylaxis, expected Q4 of 2024. Fast Track Designation given by the FDA for the use of INZ-701 for the treatment of patients with ABCC6 Deficiency. Meeting with FDA to discuss potential of initiating a pivotal late-stage study using INZ-701 for the treatment of pediatric patients with ABCC6 Deficiency, expected end of 2024.

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

- Treatment with INZ-701 shown to prevent intimal proliferation in both ENPP1-deficient and wild-type mice, supporting its potential therapeutic application beyond traditional ERT -

Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function

Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented

Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH)

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc.  (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that the Company will present recently announced topline data from the Company's ongoing Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (manifesting as pseudoxanthoma elasticum, or PXE), during oral presentations at two upcoming medical conferences.

Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 from 6:40-7:10pm ET / 3:40-4:10pm PT.

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

- Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 - - Interim data from ENERGY-1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for second half of 2024 - - Cash, cash equivalents, and short-term investments as of March 31, 2024, expected to fund operations into the fourth quarter of 2025 - BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc.  (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the first quarter ended March 31, 2024, and provided business highlights. "We were extremely pleased to see preliminary evidence of improved vascular health with INZ-701 treatment in adults with ABCC6 Deficiency, providing strong support for further clinical development in this disease,” said Douglas A.

Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights

BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to one new employee to purchase shares of the Company's common stock, pursuant to the Company's 2023 Inducement Stock Incentive Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Company's compensation committee granted nonstatutory stock options to purchase up to an aggregate of 20,000 shares of the Company's common stock to the one new employee on May 1, 2024, at an exercise price of $4.61 per share, the closing price per share of the Company's common stock as reported by Nasdaq on May 1, 2024.

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) -

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Doug Treco, Ph.D., the company's chief executive officer and chairman of the board, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 from 10:15-10:55 a.m. ET.

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET - BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m.

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April –

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

- Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion - - Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion -

Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

Inozyme is a rare disease therapy developer with a lead asset, INZ-701, targeting ENPP1 Deficiency and ABCC6 Deficiency. INZ-701 has shown safety and tolerability in trials and has the potential to improve plasma PPi levels. The ENERGY-3 trial for INZ-701 is expected to enroll up to 33 pediatric patients and will have topline data in 2025.

Inozyme: A Major Catalyst Is Uncomfortably Far Off

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Douglas A. Treco, Ph.D., the Company's chief executive officer and chairman of the board, will participate at the following investor conferences:

Inozyme Pharma to Participate in Upcoming Investor Conferences

– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 –

News for Inozyme Pharma, Inc. Stock (INZY)